| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.45 | 9e-39 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.37 | 2e-26 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.33 | 3e-21 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.3 | 3e-17 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.28 | 8e-16 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-14 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.38 | 8e-14 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.35 | 1e-10 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.2 | 2e-10 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-09 |